Access the full text.
Sign up today, get DeepDyve free for 14 days.
Sasitorn Siritho, I. Nakashima, Toshiyuki Takahashi, K. Fujihara, Naraporn Prayoonwiwat (2011)
AQP4 antibody–positive Thai casesNeurology, 77
PJ Waters, A McKeon, MI Leite (2012)
Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays., 78
N. Collongues, P. Cabre, R. Marignier, H. Zéphir, C. Papeix, B. Audoin, C. Lebrun-Frénay, J. Pelletier, B. Fontaine, P. Vermersch, C. Confavreux, J. Seze (2011)
A benign form of neuromyelitis optica: does it exist?Archives of neurology, 68 7
M. Ortega, Leticia Tornes, K. Rammohan (2013)
NMO spectrum presenting as partial myelitisMultiple Sclerosis Journal, 19
(2002)
Proposed diagnostic criteria and nosology of acute transverse myelitis.Neurology, 59 4
K. Chan, D. Ramsden, Y. Yu, K. Kwok, A. Chu, Philip Ho, J. Kwan, Regina Lee, E. Lim, M. Kung, S. Ho (2009)
Neuromyelitis optica‐IgG in idiopathic inflammatory demyelinating disorders amongst Hong Kong ChineseEuropean Journal of Neurology, 16
T. Scott, Salima Kassab, S. Pittock (2006)
Neuromyelitis optica IgG status in acute partial transverse myelitis.Archives of neurology, 63 10
B. Banwell, S. Tenembaum, V. Lennon, E. Ursell, Julia Kennedy, A. Bar-Or, B. Weinshenker, C. Lucchinetti, S. Pittock (2008)
Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disordersNeurology, 70
D. Wingerchuk, William Hogancamp, P. O'brien, B. Weinshenker (1999)
The clinical course of neuromyelitis optica (Devic’s syndrome)Neurology, 53
C. Polman, S. Reingold, B. Banwell, M. Clanet, Jeffrey Cohen, M. Filippi, K. Fujihara, E. Havrdová, M. Hutchinson, L. Kappos, F. Lublin, X. Montalban, P. O'Connor, M. Sandberg-wollheim, A. Thompson, E. Waubant, B. Weinshenker, J. Wolinsky (2011)
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 69
S Siritho, I Nakashima, T Takahashi, K Fujihara, N Prayoonwiwat (2011)
AQP4 antibody-positive Thai cases: clinical features and diagnostic problems., 77
Yujuan Jiao, J. Fryer, V. Lennon, A. McKeon, S. Jenkins, Carin Smith, A. Quek, B. Weinshenker, D. Wingerchuk, E. Shuster, C. Lucchinetti, S. Pittock (2014)
Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis.JAMA neurology, 71 1
Iain Jordan, Declan Murray (2014)
Thalamic glutamate/glutamine in restless legs syndrome: Increased and related to disturbed sleepNeurology, 82
N. Asgari, H. Skejoe, S. Lillevang, T. Steenstrup, E. Stenager, K. Kyvik (2013)
Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive studyBMC Neurology, 13
Sung-Min Kim, M. Go, J. Sung, K. Park, Kwang‐Woo Lee (2012)
Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics.Archives of neurology, 69 8
B. Weinshenker, D. Wingerchuk, S. Vukusic, L. Linbo, S. Pittock, C. Lucchinetti, V. Lennon (2006)
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitisAnnals of Neurology, 59
D. Sato, I. Nakashima, Toshiyuki Takahashi, T. Misu, P. Waters, H. Kuroda, S. Nishiyama, Chihiro Suzuki, Y. Takai, K. Fujihara, Y. Itoyama, M. Aoki (2013)
Aquaporin-4 antibody–positive cases beyond current diagnostic criteria for NMO spectrum disordersNeurology, 80
D. Wingerchuk, V. Lennon, S. Pittock, C. Lucchinetti, B. Weinshenker (2006)
Revised diagnostic criteria for neuromyelitis opticaNeurology, 66
S. Pittock, V. Lennon, N. Bakshi, L. Shen, A. McKeon, H. Quach, F. Briggs, A. Bernstein, C. Schaefer, L. Barcellos (2014)
Seroprevalence of aquaporin-4-IgG in a northern California population representative cohort of multiple sclerosis.JAMA neurology, 71 11
N. Asgari, H. Skejoe, V. Lennon (2013)
Evolution of longitudinally extensive transverse myelitis in an aquaporin-4 IgG-positive patientNeurology, 81
Su-Hyun Kim, Woojun Kim, Xue Li, I. Jung, H. Kim (2012)
Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?Multiple Sclerosis Journal, 18
M. Mealy, D. Wingerchuk, B. Greenberg, M. Levy (2012)
Epidemiology of neuromyelitis optica in the United States: a multicenter analysis.Archives of neurology, 69 9
R. Gross (2012)
Serologic diagnosis of NMO: A multicenter comparison of
V. Lennon, D. Wingerchuk, T. Kryzer, S. Pittock, C. Lucchinetti, K. Fujihara, I. Nakashima, B. Weinshenker (2004)
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosisThe Lancet, 364
ImportanceShort transverse myelitis (STM; <3 vertebral segments) is considered noncharacteristic of neuromyelitis optica (NMO) spectrum disorders (NMOSDs). Nonappreciation of the potential for STM to occur in NMOSD may lead to increased disability from delay in diagnosis and appropriate treatment. ObjectivesTo determine the frequency of short lesions at the initial myelitis manifestation of NMOSD and to compare the demographic, clinical, and radiological characteristics of aquaporin-4-IgG (AQP4-IgG) seropositive and seronegative STM. Design, Setting, and ParticipantsWe reviewed the records and images of patients at the Mayo Clinic who were identified as AQP4-IgG positive from 1996 to 2014. Inclusion criteria were first STM episode, magnetic resonance imaging performed 90 days or less from symptom onset, spinal cord T2-hyperintense lesion less than 3 vertebral segments, AQP4-IgG seropositivity, and a final diagnosis of NMO or NMOSD. Patients with an initial longitudinally extensive transverse myelitis were excluded (n = 151). Patients with STM who were seronegative for AQP4-IgG among an Olmsted County population–based cohort of inflammatory demyelinating disorders of the central nervous system were used as a control group. Main Outcomes and MeasuresDelay to diagnosis in months, clinical and radiological characteristics, and disability measured by ambulatory status. ResultsTwenty-five patients who were AQP4-IgG seropositive with an initial STM represented 14% of initial myelitis episodes among patients with NMOSD. The STM episode was defined as the first manifestation of NMOSD in 10 patients (40%) preceded by optic neuritis in 13 patients (52%) and preceded by a nausea and vomiting episode in 2 patients (8%). In comparison with the excluded patients with NMOSD who had an initial longitudinally extensive transverse myelitis, delay to diagnosis/treatment was greater when initial lesions were short (P = .02). In AQP4-IgG–positive STM cases, subsequent myelitis episodes were longitudinally extensive in 92%. Attributes more common in patients with AQP4-IgG–positive STM than in 27 population-based patients with AQP4-IgG–negative STM included the following: nonwhite race/ethnicity; tonic spasms; coexisting autoimmunity; magnetic resonance imaging (central cord lesions, T1 hypointensity, and a brain inconsistent with multiple sclerosis); and cerebrospinal fluid (oligoclonal bands lacking). Conclusions and RelevanceShort transverse myelitis is not uncommon in NMOSD and, when it is present, delays diagnosis and treatment. Clinical and radiological characteristics identified in this study may help select patients with STM who are at the highest risk for an NMOSD. Short transverse myelitis does not exclude consideration of AQP4-IgG testing or NMOSD diagnosis.
JAMA Neurology – American Medical Association
Published: Jan 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.